NCT00095290

Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria

Irbesartan Versus Placebo in Combination With Standard Cardiovascular Protection ACE-I Therapy With Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 400 (planned)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 55 Years
• Healthy volunteers: Not accepted

Summary

Albumin in the urine is usually a signal that you might be at risk of cardiovascular complications. The purpose of this study is to determine if the albumin in your urine can be decreased by the treatment regimen that consists of irbesartan taken at the same time with ramipril.

Conditions

• Albuminuria

Interventions

Type	Name	Description
DRUG	Ramipril + Irbesartan	Tablets + Capsules, Oral, 10mg Ramipril + 300mg Irbesartan target dose, Once daily, 20 weeks.
DRUG	Ramipril + Placebo	Tablets + Capsules, Oral, 10mg Ramipril + 300mg Placebo target dose, Once daily, 20 weeks.

Timeline

• Start date: 2004-09-01
• Primary completion: 2005-11-01
• Completion: 2005-11-01
• First posted: 2004-11-03
• Last updated: 2011-04-15

Locations

92 sites across 14 countries: United States, Australia, Canada, France, Germany, Israel, Italy, Latvia, Lithuania, Mexico, Netherlands, Russia, Spain, United Kingdom